David McDermott, MD of the Dana-Farber/Harvard Cancer Center outlines and Defines Optimal 2nd Line Treatment and Sequence: Subgroup Analysis from Pivotal Studies and Real World Data at the 12th European International Kidney Cancer Symposium 2017
Define Optimal 2nd Line Treatment and Sequence: Subgroup Analysis from Pivotal Studies and Real World Data
